Clinical & Translational Oncology最新文献

筛选
英文 中文
Reassessing the evidence for HER2 discordance between primary and metastatic gastric cancer: a letter to the editor. 重新评估原发性和转移性胃癌之间HER2不一致的证据:致编辑的一封信。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-15 DOI: 10.1007/s12094-026-04607-y
Shing Cheng Tan, Muhammad-Redha Abdullah-Zawawi
{"title":"Reassessing the evidence for HER2 discordance between primary and metastatic gastric cancer: a letter to the editor.","authors":"Shing Cheng Tan, Muhammad-Redha Abdullah-Zawawi","doi":"10.1007/s12094-026-04607-y","DOIUrl":"https://doi.org/10.1007/s12094-026-04607-y","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intratumoral microbiota: novel perspectives on pathogenesis, immune microenvironment and clinical translation of nasopharyngeal carcinoma. 肿瘤内微生物群:鼻咽癌发病机制、免疫微环境和临床转化的新视角。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-14 DOI: 10.1007/s12094-026-04616-x
Yilian Xu, Liang Gong, Jie Lu, Mengchuan Wang
{"title":"Intratumoral microbiota: novel perspectives on pathogenesis, immune microenvironment and clinical translation of nasopharyngeal carcinoma.","authors":"Yilian Xu, Liang Gong, Jie Lu, Mengchuan Wang","doi":"10.1007/s12094-026-04616-x","DOIUrl":"https://doi.org/10.1007/s12094-026-04616-x","url":null,"abstract":"<p><p>Nasopharyngeal carcinoma (NPC) is an epithelial malignancy characterized by marked geographic heterogeneity, with a high endemic prevalence in East and Southeast Asia. Despite advances in radiotherapy, chemotherapy, and immunotherapy, the prognosis of locally advanced and metastatic NPC remains suboptimal, creating an urgent need for novel pathogenic insights and therapeutic targets. Recent metagenomic and multi-omics studies have revealed that intratumoral microbial communities, including viruses, bacteria, and fungi, are profoundly implicated in tumor initiation, treatment response, and clinical outcomes. NPC has become a focus of research into tumor-resident microbiota and host-microbe interactions. This review summarizes the compositional characteristics, colonization pathways, and spatial distribution of the microbial community in NPC, with a focus on the molecular mechanisms of Epstein-Barr virus (EBV) and other intratumoral microorganisms in regulating inflammation, genomic stability, and anti-tumor immunity. We further summarized the clinical application of intratumoral microbiota in the development of diagnostic biomarkers, prognostic stratification, and precise treatment. This includes non-invasive screening that combines microbial characteristics with EBV DNA, microbiota-mediated chemoradiotherapy, enhanced immune checkpoint inhibitors, and emerging models, such as engineered bacteria and phage therapy. Finally, we analyzed key challenges, such as low-biomass detection, standardization, and interindividual heterogeneity, while looking ahead to future directions in spatial multi-omics, AI-driven data integration, and interdisciplinary collaboration to advance precision medicine for NPC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repeat stereotactic radiosurgery for recurrent brain metastases: safety and durable local control in a single-centre series of 132 metastases. 重复立体定向放射手术治疗复发性脑转移:132例转移的单中心系列的安全性和持久的局部控制。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-12 DOI: 10.1007/s12094-026-04573-5
Luis Aznar-García, Bruno E Zambrana-Moreno
{"title":"Repeat stereotactic radiosurgery for recurrent brain metastases: safety and durable local control in a single-centre series of 132 metastases.","authors":"Luis Aznar-García, Bruno E Zambrana-Moreno","doi":"10.1007/s12094-026-04573-5","DOIUrl":"https://doi.org/10.1007/s12094-026-04573-5","url":null,"abstract":"<p><strong>Background: </strong>Local progression (LP) after stereotactic radiosurgery (SRS) for brain metastases (BM) presents a therapeutic challenge and evidence for repeat SRS (ReSRS) is limited. This study reports outcomes of second (SRS2) and third (SRS3) SRS courses for recurrent BM.</p><p><strong>Methods: </strong>We retrospectively analysed patients treated with ReSRS between 2016 and 2025 at our institution. Clinical, radiological, and dosimetric variables were collected. Local progression-free survival (L-PFS), radionecrosis, and radiological response were analysed. Predictors of LP and radionecrosis were evaluated with univariate and multivariate analyses.</p><p><strong>Results: </strong>132 BM in 96 patients were included. SRS2 (132 BM) and SRS3 (14 BM) achieved 12-month local control rates of 78.7 and 67.0%, respectively. Median L-PFS after SRS2 was 47.1 months. Independent predictors of LP after SRS2 were BED₁₂Gy < 53.6 Gy at SRS1 (p = 0.014) and fractionated SRS2 (p = 0.042), but not confirmed with further analysis. The incidence of radiological radionecrosis following SRS2 was 40.9%, with rates of 28.0%, 36.4, and 38.6% at 6, 12, and 24 months, respectively. Symptomatic radionecrosis occurred in 14.6% of patients, and all of them improved with corticosteroid treatment. Clinical improvement was observed in 42.2%, while 92.4% showed radiological stability/response after SRS2. No treatment-related deaths were observed.</p><p><strong>Conclusions: </strong>ReSRS is a safe and effective salvage approach for recurrent BM offering durable local control, favourable clinical outcomes, and acceptable adverse events. Prospective studies are needed to refine patient selection and improve risk stratification.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of screening for melanoma and keratinocyte carcinoma: a systematic review and meta-analysis. 黑色素瘤和角化细胞癌筛查的有效性:一项系统综述和荟萃分析。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-11 DOI: 10.1007/s12094-026-04604-1
Min Zhou, Hongwei Tang, Lei Lei, Mingxing Liu
{"title":"Effectiveness of screening for melanoma and keratinocyte carcinoma: a systematic review and meta-analysis.","authors":"Min Zhou, Hongwei Tang, Lei Lei, Mingxing Liu","doi":"10.1007/s12094-026-04604-1","DOIUrl":"https://doi.org/10.1007/s12094-026-04604-1","url":null,"abstract":"<p><strong>Background: </strong>Skin cancer screening may facilitate earlier diagnosis, but potential benefits must be balanced against unnecessary procedures, overdiagnosis, costs, and harms. We evaluated randomized screening, high-risk surveillance, and diagnostic-triage interventions for melanoma and keratinocyte carcinoma.</p><p><strong>Methods: </strong>MEDLINE, Scopus, Web of Science Core Collection, and CENTRAL were searched through July 2026. Randomized trials involving community populations, high-risk groups, or patients with suspicious lesions were eligible. Two reviewers independently selected studies and extracted data. Clinician-performed skin examination attendance was synthesized using restricted maximum-likelihood random-effects estimation with Hartung-Knapp adjustment. Clinically incompatible outcomes were summarized individually. Risk of bias and certainty were assessed using RoB 2 and GRADE.</p><p><strong>Results: </strong>Fourteen publications representing 13 independent randomized trial families were included. Three trials contributed to the screening attendance analysis. The pooled odds ratio (OR) was 1.16 (95% CI 0.81-1.66; P  =  .215; I2  =  0.0%), indicating no significant improvement. Intensive digital surveillance did not significantly alter melanoma detection (risk ratio [RR], 0.65; 95% CI 0.38-1.10) or keratinocyte carcinoma detection (RR, 1.32; 95% CI 0.96-1.83), but increased participants undergoing excision (RR, 1.16; 95% CI 1.01-1.33). Reflectance confocal microscopy reduced index lesion excisions (RR, 0.54; 95% CI 0.51-0.56). Teledermoscopy improved diagnostic sensitivity and specificity, whereas mobile-assisted self-examination showed lower lesion-level sensitivity than naked-eye examination. Seven publications (50.0%) had high risk of bias, and 10 of 11 outcomes had very low certainty evidence.</p><p><strong>Conclusions: </strong>Screening-promotion interventions did not significantly improve clinician examination attendance. Diagnostic technologies altered selected decisions and procedures, but evidence remained insufficient to establish consistent patient-relevant net clinical benefit.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of risk-stage classification in patients with stage III melanoma: results from the real-world GEM1801 Spanish registry. 风险分期分类在III期黑色素瘤患者中的预后价值:来自真实世界GEM1801西班牙注册的结果
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-11 DOI: 10.1007/s12094-026-04601-4
Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, José Luis Manzano, Miguel-Ángel Berciano-Guerrero, Pablo Ayala de Miguel, Eva Muñoz-Couselo, Teresa Puértolas, Carlos Aguado de la Rosa, Guillermo Crespo, Lorena Bellido, Mª José Lecumberri, José Carlos Villa Guzmán, Marta Sotelo, Lourdes Gutiérrez Sanz, Maria Gonzalez-Cao, Margarita Majem, Rafael López Castro, Alberto Cunquero-Tomás, Berta Hernández, Enrique Espinosa, Begoña Campos Balea, Aida Bujosa Rodríguez, Victor Navarro Pérez, Joaquín Fra Rodríguez, Javier Medina Martínez, Alfonso Berrocal, Salvador Martín Algarra, Iván Márquez-Rodas
{"title":"Prognostic value of risk-stage classification in patients with stage III melanoma: results from the real-world GEM1801 Spanish registry.","authors":"Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, José Luis Manzano, Miguel-Ángel Berciano-Guerrero, Pablo Ayala de Miguel, Eva Muñoz-Couselo, Teresa Puértolas, Carlos Aguado de la Rosa, Guillermo Crespo, Lorena Bellido, Mª José Lecumberri, José Carlos Villa Guzmán, Marta Sotelo, Lourdes Gutiérrez Sanz, Maria Gonzalez-Cao, Margarita Majem, Rafael López Castro, Alberto Cunquero-Tomás, Berta Hernández, Enrique Espinosa, Begoña Campos Balea, Aida Bujosa Rodríguez, Victor Navarro Pérez, Joaquín Fra Rodríguez, Javier Medina Martínez, Alfonso Berrocal, Salvador Martín Algarra, Iván Márquez-Rodas","doi":"10.1007/s12094-026-04601-4","DOIUrl":"https://doi.org/10.1007/s12094-026-04601-4","url":null,"abstract":"<p><strong>Background: </strong>There is limited real-world data (RWD) in Spain regarding the prognostic value of the 8th American Joint Cancer Committee (AJCC) staging system in patients with melanoma, especially regarding the use of adjuvant treatment across stage III subcategories. Additional factors could refine risk stratification.</p><p><strong>Methods: </strong>This study aimed to analyse the outcomes of patients with resectable stage III melanoma in Spain included in the observational ambispective GEM1801 study. Relapse-free survival (RFS) and overall survival (OS) were determined. Prognostic factors were analysed.</p><p><strong>Results: </strong>Between Aug 2018- Jan 2025, 346 patients with stage III were included. Patients had stage IIIA (12.4%), IIIB (24.0%), IIIC (58.7%), and IIID (4.9%). 121 (35.0%) were clinically detectable (Nb/Nc). The median age was 64 years, and 58.1% were male. Adjuvant therapy was administered to 257 patients (74.3%). Stage was an independent prognostic factor for RFS and OS, with 2-year RFS/OS rates of 90%/94% for IIIA, 74%/90% for IIIB, 61%/83% for IIIC, and 28%/52% for IIID. Sex was an independent prognostic factor for RFS (Hazard Ratio 1.7, 95% CI 1.0-2.8; male vs. female) and age for OS (Hazard Ratio 3.6, 95% CI 1.9-6.7; >65 vs. ≤65 years).</p><p><strong>Conclusions: </strong>AJCC 8th edition staging has a good prognostic correlation in patients with stage III melanoma in Spain. Sex and age were prognostic suggesting their inclusion for risk stratification. CLINICAL TRIAL IDENTIFICATION: clinicaltrials.gov: NCT03605771.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-L1 testing in cutaneous malignancies: interpretation, clinical utility, and unresolved challenges. PD-L1检测在皮肤恶性肿瘤:解释,临床应用,和未解决的挑战。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-11 DOI: 10.1007/s12094-026-04605-0
Abdulhadi Samman
{"title":"PD-L1 testing in cutaneous malignancies: interpretation, clinical utility, and unresolved challenges.","authors":"Abdulhadi Samman","doi":"10.1007/s12094-026-04605-0","DOIUrl":"https://doi.org/10.1007/s12094-026-04605-0","url":null,"abstract":"<p><p>Immune checkpoint inhibitors have transformed the management of melanoma, cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC), basal cell carcinoma (BCC), and selected rare cutaneous malignancies, yet the clinical value of programmed death-ligand 1 (PD-L1) immunohistochemistry has not kept pace with the therapeutic importance of the PD-1/PD-L1 pathway. This narrative review, prepared according to the SANRA quality criteria, evaluates PD-L1 testing at four linked levels: what PD-L1 expression represents biologically, how reliably it can be measured, whether it is prognostic or predictive, and whether the result changes clinical management. PD-L1 expression is inducible, spatially and temporally heterogeneous, and present on tumor and immune cells, and its measurement depends on specimen, clone, platform, scored compartment, and cutoff. In melanoma, tumor-cell PD-L1 enriches for response at the cohort level, but PD-L1-negative tumors respond to PD-1 blockade, and the only label that mandates testing is the European authorization of nivolumab-relatlimab for tumor-cell PD-L1 < 1%. In cSCC, MCC, and BCC, checkpoint inhibitors are approved without PD-L1 selection, and no PD-L1 companion diagnostic is approved for any cutaneous malignancy. PD-L1 should therefore be reported with the specimen, clone, platform, compartment, scoring system, and cutoff, and interpreted only within a defined tumor and therapeutic context. Composite approaches that integrate tumor immunogenicity, CD8-positive T cell spatial organization, interferon-gamma signaling, viral status, circulating tumor DNA, and multiplex or digital pathology are more likely than PD-L1 alone to improve treatment selection, but they must demonstrate incremental, reproducible clinical utility.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant PD-1 or PD-L1 blockade for Merkel cell carcinoma: a systematic review and meta-analysis. 辅助PD-1或PD-L1阻断治疗默克尔细胞癌:系统回顾和荟萃分析
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-03 DOI: 10.1007/s12094-026-04600-5
Imad Barjij, Sarah Naciri, Meryem Meliani, Badr Cherradi, Youssef Aghlallou, Ryan S Huang, Sihame Lkhoyaali, Hanane Inrhaouen, Ibrahim Elghissassi, Saber Boutayeb, Hind Mrabti, Hassan Errihani
{"title":"Adjuvant PD-1 or PD-L1 blockade for Merkel cell carcinoma: a systematic review and meta-analysis.","authors":"Imad Barjij, Sarah Naciri, Meryem Meliani, Badr Cherradi, Youssef Aghlallou, Ryan S Huang, Sihame Lkhoyaali, Hanane Inrhaouen, Ibrahim Elghissassi, Saber Boutayeb, Hind Mrabti, Hassan Errihani","doi":"10.1007/s12094-026-04600-5","DOIUrl":"https://doi.org/10.1007/s12094-026-04600-5","url":null,"abstract":"<p><strong>Purpose: </strong>To estimate the effect of adjuvant programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade after definitive local therapy for Merkel cell carcinoma (MCC) and assess certainty and applicability.</p><p><strong>Methods: </strong>We prospectively registered this systematic review and meta-analysis (PROSPERO CRD420261491127). Randomized trials comparing adjuvant PD-1 or PD-L1 blockade with no systemic adjuvant therapy after definitive local treatment for MCC were identified through six databases, registries, congress sources, reference lists, and citation searches through September 9, 2026. Two reviewers selected studies, extracted data, and assessed risk of bias and certainty. Hazard ratios (HRs) for recurrence or death were pooled using random-effects modified Hartung-Knapp inference.</p><p><strong>Results: </strong>Four randomized trials were eligible; 3 trials with results included 572 participants. All point estimates favored blockade, but each confidence interval (CI) included the null. The pooled HR for recurrence or death was 0.70 (95% CI, 0.36-1.38). At a representative 24-month control event-free probability of 695 per 1000, this corresponded to 80 more participants per 1000 remaining event free (95% CI, 90 fewer to 184 more). Overall survival and safety could not be pooled. Certainty was very low for all critical outcomes.</p><p><strong>Conclusions: </strong>Adjuvant PD-1 or PD-L1 blockade may reduce recurrence or death after definitive local therapy for MCC, but evidence remains compatible with benefit, little or no effect, or harm. Routine class-wide use is not established; decisions should remain individualized pending mature survival and harmonized safety data.</p><p><strong>Registration: </strong>PROSPERO CRD420261491127.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis. 预处理抗生素暴露和非小细胞肺癌免疫检查点抑制剂治疗后的死亡率:感染分层倾向匹配分析
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-02 DOI: 10.1007/s12094-026-04599-9
Parsa Radfar, Andrei I Gritsiuta, Margaux Marinelli, Joshua Yazditabar, Shawn P Nishi, Maurice Willis, Roman V Petrov
{"title":"Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis.","authors":"Parsa Radfar, Andrei I Gritsiuta, Margaux Marinelli, Joshua Yazditabar, Shawn P Nishi, Maurice Willis, Roman V Petrov","doi":"10.1007/s12094-026-04599-9","DOIUrl":"https://doi.org/10.1007/s12094-026-04599-9","url":null,"abstract":"<p><strong>Purpose: </strong>Pretreatment antibiotic exposure has been associated with inferior outcomes during immune checkpoint inhibitor (ICI) therapy, but whether this reflects an ICI specific effect or underlying clinical vulnerability remains uncertain.</p><p><strong>Methods: </strong>Adults with non-small cell lung cancer (NSCLC) treated with ICIs from 2015 through 2024 were identified in the TriNetX Research Network. Recent antibiotic exposure was defined as systemic antibiotic use during days 30 to 1 before ICI initiation. Propensity score matching balanced clinical and treatment-related covariates. Primary outcomes were all cause mortality at 90 and 365 days. Sensitivity analyses included landmarking, remote exposure, infection stratification, and a non-ICI comparator.</p><p><strong>Results: </strong>Among 68,723 patients, 19,080 had recent antibiotic exposure; 17,955 per group remained after matching. Mortality was higher with antibiotic exposure at 90 days (17.7% vs 13.7%; HR 1.34, 95% CI 1.27 to 1.41; P<0.001) and 365 days (43.0% vs 37.2%; HR 1.23, 95% CI 1.19 to 1.27; P<0.001). Associations attenuated after exclusion of early deaths. The association was similar between ICI and non-ICI cohorts at 90 days but modestly stronger with ICI at 365 days. Remote exposure did not reproduce the adverse association.</p><p><strong>Conclusions: </strong>Recent antibiotic exposure was associated with increased mortality during ICI therapy, but the non-ICI comparison and landmark analyses suggest that much of the short-term excess mortality reflects clinical vulnerability rather than an ICI specific effect. The modestly stronger 1-year association with ICI therapy is hypothesis generating.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic body radiotherapy for non-spinal bone oligometastases: a mono-institutional experience. 立体定向放射治疗非脊柱骨少转移:单一机构的经验。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-01 Epub Date: 2026-06-06 DOI: 10.1007/s12094-026-04444-z
Francesco Cuccia, Gianluca Mortellaro, Marina Campione, Daniela Cespuglio, Salvatore D'Alessandro, Vanessa Figlia, Antonio Spera, Francesco Azzarello, Carlo Messina, Livio Blasi, Giuseppe Carruba, Giuseppe Ferrera
{"title":"Stereotactic body radiotherapy for non-spinal bone oligometastases: a mono-institutional experience.","authors":"Francesco Cuccia, Gianluca Mortellaro, Marina Campione, Daniela Cespuglio, Salvatore D'Alessandro, Vanessa Figlia, Antonio Spera, Francesco Azzarello, Carlo Messina, Livio Blasi, Giuseppe Carruba, Giuseppe Ferrera","doi":"10.1007/s12094-026-04444-z","DOIUrl":"10.1007/s12094-026-04444-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Stereotactic body radiotherapy (SBRT) has entered daily clinical practice in the management of oligometastatic disease. Similarly to the evidence in support of spinal metastases, the use of SBRT has been recently reported also for the treatment of non-spinal bone metastases (NSBM).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This is a single-institutional experience of oligometastatic patients treated with SBRT for NSBM. Oligometastases were defined according to the recent ESTRO/EORTC consensus. Inclusion criteria were as follows: ECOG PS ≤ 2, written informed consent, up to 5 lesions to be treated at the same time, and treatment with radiotherapy schedules applying a minimum of 6 Gy per fraction. The primary endpoint of the study was local control (LC); acute and late toxicity, distant progression-free survival (DPFS), time-to-next systemic treatment (TNST), and overall survival (OS) were secondary endpoints. Toxicity was assessed according to CTCAE criteria v5.0. Survival estimates were performed using the Kaplan-Meier method, uni- and multi-variate analyses were carried out to identify any potentially significant correlation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 74 bone oligometastases in 52 patients were treated in our institution between February 2020 and December 2024. All patients received SBRT with Helical Tomotherapy for a median total dose of 33.7 Gy (range, 24-35 Gy) delivered in 3-5 fractions. In 51.9% of cases, SBRT was delivered to oligoprogressive lesions, to oligorecurrent lesions in 42.3%, while the remaining were patients with synchronous oligometastases and primary disease. Prostate cancer was the most frequent primary histology in 50% of cases, followed by breast (26.9%), uterus (7.7%), NSCLC (5.8%). Median age was 70 years (range 49-88), Males = 30; Females = 22). In the majority of patients (73%) SBRT was delivered to a single oligometastasis, with up to 4 NSBM treated simultaneously, with the thorax the most frequent site of SBRT (53.8%), followed by the pelvis (46.1%). Concurrent systemic therapy was administered in 55.8% of patients. After a median follow-up of 31.8 months (range, 12-33.4), 1- and 2-year LC rates were respectively 98.1% and 96%, while DPFS rates were 57.7% and 31.5%. 1- and 2-year TNST were respectively 82.7% and 42.9% with worse outcomes for patients with oligoprogressive disease at univariate analysis (p = 0.018). Concerning OS, 1- and 2-year rates were, respectively, 94.3% and 90%, with a statistically significant relation with male gender and prostate histology for improved outcomes (p = 0.003 and p = 0.004); also &gt; 1 metastasis treated was reported to correlate with lower OS rates (p = 0.016). No G ≥ 3 adverse events were observed, with 15.4% of cases developing acute G2 pain after SBRT, fully resolved after oral steroids.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In our experience, SBRT for NSBM was safe and effective with minimal toxicity and excellent results in terms of LC. Pr","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"5479-5491"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance. 西班牙hpv相关癌症预防:疫苗接种、筛查和监测方面的进展和仍然存在的挑战。
IF 2.7 3区 医学
Clinical & Translational Oncology Pub Date : 2026-11-01 Epub Date: 2026-06-06 DOI: 10.1007/s12094-026-04447-w
Alejandro Gallego Martínez, Antonio Gonzalez-Martin, Luis Chiva de Agustin
{"title":"HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance.","authors":"Alejandro Gallego Martínez, Antonio Gonzalez-Martin, Luis Chiva de Agustin","doi":"10.1007/s12094-026-04447-w","DOIUrl":"10.1007/s12094-026-04447-w","url":null,"abstract":"<p><p>Human papillomavirus (HPV) is a necessary causal factor for most cervical cancers and contributes to several other HPV-related malignancies. The nonavalent HPV vaccine targets the most prevalent oncogenic genotypes and has the potential to prevent up to 90% of HPV-attributable cancers. However, cervical cancer screening remains essential, as vaccination does not cover all oncogenic HPV genotypes, does not treat established HPV infection, and cannot prevent disease in individuals after HPV exposure. Available Spanish data do not yet show a clear sustained decline in HPV-related cancers comparable to that reported in some other high-income countries. This narrative review examines HPV vaccination, cervical cancer screening, and the burden of HPV-related cancers in Spain, with a focus on implementation gaps, surveillance limitations, and opportunities for improvement. Strengthening vaccination coverage, population-based screening, follow-up after abnormal results, and national data integration will be essential to accelerate progress toward cervical cancer elimination.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"5143-5153"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13694566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书